PRESCRIPTION NOTICE: Propranolol 40 mg is a Prescription Only Medicine (POM). It cannot legally be dispensed without a valid prescription from a licensed healthcare provider in Kenya. Do not use this medicine without medical supervision. Do not share this medicine with others even if they appear to have the same condition.
Propranolol 40 mg Tablets are a prescription-only non-selective beta-adrenergic receptor blocker — one of the oldest, most extensively studied, and most clinically versatile beta-blockers in global and Kenyan medical practice. Each pack contains 25 tablets of propranolol hydrochloride 40 mg, a medicine with an exceptionally broad range of indications spanning cardiovascular, neurological, endocrine, and psychiatric conditions.
Unlike the newer, more cardioselective beta-blockers such as bisoprolol (Concor) and nebivolol, propranolol blocks both beta-1 adrenergic receptors in the heart and beta-2 adrenergic receptors in the bronchi, peripheral blood vessels, and other tissues — a non-selective profile that underpins both its wide range of clinical applications and its important contraindications, particularly in patients with asthma or COPD. Propranolol is included on the Kenya Essential Medicines List (KEML) and remains one of the most prescribed beta-blockers in Kenya due to its established efficacy, clinical versatility, and affordability. If you have been prescribed Propranolol 40 mg in Kenya, this medicine must be taken strictly as directed by your healthcare provider. The price of Propranolol 40 mg in Kenya is among the most accessible of all prescription antihypertensives, and it is dispensed only on presentation of a valid prescription.
Key Benefits
- Broad clinical versatility — one of the widest ranges of approved indications of any beta-blocker, covering cardiovascular, neurological, endocrine, and anxiety-related conditions
- Effective antihypertensive — reduces blood pressure through cardiac output reduction and RAAS suppression
- Proven antianginal efficacy — reduces myocardial oxygen demand, decreasing angina frequency and improving exercise tolerance
- Effective antiarrhythmic — controls heart rate and ventricular response in multiple arrhythmia types
- Migraine prophylaxis — one of the most evidence-supported non-selective beta-blockers for preventing migraine attacks
- Anxiety and situational tremor management — widely used for performance anxiety and essential tremor
- Thyrotoxicosis symptom control — rapidly controls the adrenergic symptoms of hyperthyroidism while awaiting definitive treatment
- Portal hypertension — reduces the risk of variceal bleeding in patients with liver cirrhosis
- Included on the Kenya Essential Medicines List (KEML) — recognised as an essential medicine for Kenyan healthcare
- Affordable and widely available — one of the most cost-effective beta-blockers available in Kenya
What It Is & How It Works
Active Ingredient
Each tablet contains:
| Active Ingredient | Strength | Role |
|---|---|---|
| Propranolol Hydrochloride | 40 mg | Non-selective beta-1 and beta-2 adrenergic receptor blocker — reduces heart rate, cardiac output, blood pressure, and adrenergic stimulation across multiple organ systems |
How It Works
Propranolol competitively and non-selectively blocks both beta-1 and beta-2 adrenergic receptors throughout the body, preventing catecholamines — primarily adrenaline (epinephrine) and noradrenaline (norepinephrine) — from binding to and activating these receptors. The pharmacological consequences of this non-selective beta blockade are extensive and clinically significant:
Beta-1 Receptor Blockade (Cardiac Effects)
Beta-1 receptors are located predominantly in the heart. Propranolol’s beta-1 blockade produces:
- Negative chronotropy — reduces resting and exercise heart rate by slowing spontaneous depolarisation of the sinoatrial (SA) node
- Negative inotropy — reduces the force and velocity of myocardial contraction, lowering cardiac output and blood pressure
- Negative dromotropy — slows conduction through the atrioventricular (AV) node, reducing ventricular rate in supraventricular arrhythmias including atrial fibrillation and flutter
- Suppression of renin release — propranolol inhibits beta-1 receptor-mediated renin secretion from the juxtaglomerular apparatus of the kidney, reducing RAAS activation and contributing to blood pressure lowering
- Reduction in myocardial oxygen demand — by reducing heart rate, contractility, and blood pressure, propranolol substantially reduces the oxygen requirements of the myocardium, relieving angina
Beta-2 Receptor Blockade (Peripheral and Pulmonary Effects)
Beta-2 receptors are found in bronchial smooth muscle, peripheral blood vessels, the liver, skeletal muscle, and other tissues. Propranolol’s beta-2 blockade produces:
- Bronchospasm — blockade of beta-2 receptors in bronchial smooth muscle prevents bronchodilation and can cause clinically significant bronchoconstriction in susceptible individuals — the most important safety concern with non-selective beta-blockade and the primary reason propranolol is absolutely contraindicated in asthma and severe COPD
- Peripheral vasoconstriction — blockade of beta-2 receptors in peripheral blood vessels prevents vasodilation, which can worsen cold extremities and peripheral artery disease
- Inhibition of glycogenolysis and gluconeogenesis — beta-2 blockade in the liver and skeletal muscle reduces glucose mobilisation in response to hypoglycaemia and may both mask hypoglycaemia symptoms and impair recovery from hypoglycaemia — a critical safety consideration in diabetic patients on insulin or sulphonylureas
- Suppression of tremor — beta-2 blockade in skeletal muscle reduces the peripheral adrenergic component of essential tremor and anxiety-related tremor
- Reduction of adrenergic symptoms — in thyrotoxicosis, anxiety, and phaeochromocytoma, propranolol’s beta-2 blockade rapidly suppresses the tachycardia, tremor, sweating, and anxiety driven by excessive adrenergic stimulation
Additional Mechanisms
- Membrane-stabilising activity — at high doses, propranolol exerts a quinidine-like membrane-stabilising effect on cardiac cells, contributing to its antiarrhythmic activity; this effect is not clinically significant at standard oral doses
- Central nervous system effects — propranolol crosses the blood-brain barrier more readily than more hydrophilic beta-blockers (such as atenolol), contributing to its efficacy in migraine prophylaxis, anxiety, and essential tremor through central adrenergic receptor blockade; this CNS penetration also explains its higher incidence of CNS side effects including sleep disturbances, nightmares, and depression compared to hydrophilic beta-blockers
Classification
Propranolol 40 mg is classified as a Prescription Only Medicine (POM) in Kenya. It must only be initiated, monitored, and adjusted by a licensed healthcare provider. A valid prescription is required for dispensing at any registered pharmacy in Kenya.
Formulation
Uncoated or film-coated tablets. Each pack contains 25 tablets. Tablets should be swallowed whole with water and may be taken with or without food — consistent timing relative to meals is advisable.
Uses & Indications
Propranolol 40 mg Tablets are indicated for the management of a broad range of conditions, including:
Cardiovascular Indications
- Hypertension (high blood pressure) — as monotherapy or in combination with other antihypertensive agents
- Stable angina pectoris — to reduce the frequency of angina episodes and improve exercise tolerance
- Cardiac arrhythmias — including supraventricular tachycardia, atrial fibrillation and flutter (ventricular rate control), ventricular tachycardia, and tachyarrhythmias associated with thyrotoxicosis
- Post-myocardial infarction — secondary prevention to reduce mortality and recurrent infarction risk in stable patients following acute MI
- Hypertrophic obstructive cardiomyopathy (HOCM) — symptom relief of angina and palpitations
- Fallot’s tetralogy — management of hypercyanotic spells in children
Neurological Indications
- Migraine prophylaxis — one of the most evidence-supported first-line treatments for preventing migraine attacks; reduces attack frequency and severity
- Essential tremor — particularly action and postural tremor of the hands
Anxiety and Psychiatric Indications
- Situational anxiety and performance anxiety — including public speaking anxiety, examination anxiety, and stage fright; propranolol blocks the peripheral adrenergic symptoms of anxiety (palpitations, tremor, sweating) without sedation
- Anxiety-associated tachycardia and palpitations
Endocrine Indications
- Thyrotoxicosis (hyperthyroidism) — symptomatic control of adrenergic symptoms including tachycardia, tremor, anxiety, and sweating while awaiting definitive treatment with antithyroid drugs, radioiodine, or surgery
- Phaeochromocytoma — pre-operative symptomatic control in conjunction with alpha-blockade; must never be used without prior alpha-blockade
Portal Hypertension
- Prevention of variceal bleeding — in patients with liver cirrhosis and portal hypertension; propranolol reduces portal venous pressure by reducing cardiac output and causing splanchnic vasoconstriction via beta-2 blockade
IMPORTANT: The decision to initiate, adjust, or discontinue Propranolol therapy must be made exclusively by a licensed healthcare provider. Do not self-prescribe or alter your dose without medical advice. Abrupt discontinuation of propranolol — particularly in patients with coronary artery disease, angina, or hypertension — can precipitate rebound tachycardia, hypertension, unstable angina, or acute myocardial infarction. Always taper the dose gradually under medical supervision.
Dosage & Administration
This medicine requires a valid prescription. Use only as prescribed by your healthcare provider. The following dosage information is provided for general reference only and does not constitute prescribing advice.
| Indication | Starting Dose | Usual Maintenance Dose | Maximum Daily Dose |
|---|---|---|---|
| Hypertension | As directed | As directed | As directed |
| Angina | As directed | As directed | As directed |
| Arrhythmias | As directed | As directed by physician | As directed |
| Post-MI secondary prevention | As directed | As directed | As directed |
| Migraine prophylaxis | As directed | As directed | As directed |
| Essential tremor | As directed | As directed | As directed |
| Anxiety / situational anxiety | As directed | As directed by physician | As directed |
| Thyrotoxicosis | As directed | As directed by physician | As directed |
| Portal hypertension | As directed | Titrated to reduce resting heart rate by 25% | As directed |
| Renal impairment | As directed | As directed | Standard dose |
| Hepatic impairment | As directed | As directed by physician | Reduce accordingly |
| Elderly patients | As directed | As directed | Standard dose with caution |
Administration Instructions
- Take this medicine exactly as prescribed — do not increase, decrease, or skip doses without medical advice
- May be taken with or without food — however, food increases propranolol bioavailability by reducing first-pass hepatic metabolism; take consistently with or without food to maintain predictable drug levels
- Take at the same times each day to maintain consistent blood levels — propranolol has a relatively short half-life of 3–6 hours compared to once-daily beta-blockers, necessitating multiple daily doses for most indications
- Swallow tablets whole with a full glass of water — do not crush or chew unless specifically advised
- Never stop taking propranolol suddenly without consulting your doctor — abrupt discontinuation causes dangerous rebound effects; always taper the dose gradually over 1–2 weeks under medical supervision
- If a dose is missed, take it as soon as you remember — if it is almost time for the next dose, skip the missed dose and continue as normal; do not double dose
- For situational anxiety — take a single 40 mg dose approximately 1 hour before the anticipated stressful event; do not drive or operate machinery until you know how propranolol affects you
- Attend all scheduled follow-up appointments for heart rate and blood pressure monitoring
Possible Side Effects
Like all medicines, Propranolol 40 mg may cause side effects in some patients. The side effect profile reflects both its beta-1 and beta-2 receptor blockade. Report any new or worsening symptoms to your healthcare provider promptly.
Common
- Fatigue or tiredness — particularly in the first few weeks; often improves with continued use
- Cold extremities — hands and feet may feel cold due to peripheral vasoconstriction from beta-2 blockade
- Bradycardia (slow heart rate) — heart rate below 50–60 beats per minute; report to your doctor
- Dizziness or light-headedness — particularly upon standing; rise slowly from sitting or lying positions
- Sleep disturbances, vivid dreams, or nightmares — propranolol penetrates the blood-brain barrier and has higher CNS side effects than more hydrophilic beta-blockers
- Nausea, vomiting, or abdominal discomfort
- Headache — usually mild and transient
Less Common
- Depression or low mood — CNS penetration of propranolol is associated with a higher incidence of mood disturbances compared to hydrophilic beta-blockers such as atenolol
- Mild bronchospasm — even in patients without known asthma; report any new breathlessness or wheeze immediately
- Erectile dysfunction in male patients
- Hypoglycaemia masking — propranolol may mask the tachycardia and tremor warning signs of low blood sugar in diabetic patients; sweating may remain as an indicator
- Worsening peripheral artery disease or Raynaud’s phenomenon symptoms
- Elevated triglycerides and reduced HDL cholesterol — metabolic effects of non-selective beta-blockade; monitor lipid profile in long-term use
- Memory impairment or confusion — particularly in elderly patients
WARNING: Rare but serious — seek immediate medical attention if you experience: severe bronchospasm or acute respiratory distress (even in patients not previously known to have asthma — propranolol can unmask latent bronchial hyperreactivity), severe bradycardia or AV heart block (very slow or irregular pulse), acute heart failure decompensation (sudden breathlessness, ankle swelling, or rapid weight gain), severe hypoglycaemia unawareness in diabetic patients, signs of peripheral ischaemia (severe cold, blue, or painful extremities), or severe skin reactions. In patients with phaeochromocytoma — do not use propranolol without prior alpha-blockade; doing so can cause a dangerous paradoxical hypertensive crisis.
This is not a complete list of side effects. Report all side effects to your healthcare provider.
Warnings & Precautions
CONTRAINDICATION: Do NOT use Propranolol if you have bronchial asthma or a history of bronchospasm, severe COPD, uncontrolled heart failure, cardiogenic shock, second- or third-degree AV block without a pacemaker, sick sinus syndrome, sinoatrial block, severe bradycardia (below 60 bpm at rest), severe hypotension, Prinzmetal’s (vasospastic) angina, untreated phaeochromocytoma, or metabolic acidosis, or if you are known to be hypersensitive to propranolol or any excipient in this formulation.
Do Not Use If You:
- Have bronchial asthma or any history of bronchospasm — propranolol is absolutely contraindicated; even a single dose can precipitate fatal bronchospasm in asthmatic patients
- Have severe or uncontrolled COPD — significant bronchospasm risk
- Have acute decompensated heart failure or cardiogenic shock
- Have significant bradycardia or advanced heart block without a pacemaker
- Have untreated phaeochromocytoma — propranolol without prior alpha-blockade causes paradoxical hypertensive crisis
- Have Prinzmetal’s (vasospastic) angina — beta-blockade may worsen coronary vasospasm in this condition
Use With Extreme Caution If You Have:
- Diabetes mellitus — propranolol masks hypoglycaemia symptoms (tachycardia, tremor, anxiety); only sweating may remain; significant blood glucose monitoring is essential; discuss with your doctor before use
- Mild to moderate COPD — use only under specialist supervision with careful respiratory monitoring; consider a cardioselective beta-blocker as a safer alternative
- Peripheral artery disease or Raynaud’s phenomenon — propranolol worsens peripheral circulation; use with caution
- Psoriasis — beta-blockers are associated with triggering or worsening psoriasis
- Thyrotoxicosis — do not withdraw propranolol abruptly in thyrotoxic patients; sudden withdrawal may precipitate thyroid storm
- First-degree AV block — monitor ECG during treatment
- Severe liver disease — propranolol undergoes extensive first-pass hepatic metabolism; severe hepatic impairment results in significantly elevated plasma levels; dose reduction is required
- Myasthenia gravis — beta-blockers may worsen neuromuscular transmission
Do Not Combine With (Selected Key Interactions — Consult Pharmacist for Full Review):
- Calcium channel blockers of the verapamil or diltiazem type — risk of severe bradycardia, AV block, and cardiac failure; this combination is potentially life-threatening and must be avoided
- Other antiarrhythmic agents (amiodarone, flecainide, digoxin) — additive bradycardia and AV conduction disturbances; monitor ECG closely
- Clonidine — when discontinuing both medicines, always stop propranolol first then gradually withdraw clonidine to prevent rebound hypertensive crisis
- Insulin and oral antidiabetic agents — propranolol masks hypoglycaemia; prolongs recovery from hypoglycaemia; monitor blood glucose meticulously
- NSAIDs (ibuprofen, diclofenac, aspirin) — may reduce the antihypertensive effect of propranolol
- Sympathomimetic agents (adrenaline, salbutamol) — propranolol antagonises their bronchodilatory and vasodilatory effects; may cause dangerous hypertension with adrenaline
- Antihypertensive medicines and diuretics — additive hypotensive effects
- Theophylline — propranolol inhibits theophylline metabolism, increasing theophylline plasma levels and toxicity risk; also antagonises theophylline’s bronchodilatory effect
- Ergotamine — risk of peripheral vasoconstriction and ischaemia
- Alcohol — additive hypotensive effects; avoid excessive alcohol consumption
- Lidocaine — propranolol increases lidocaine plasma levels by reducing hepatic blood flow; monitor for lidocaine toxicity
- Warfarin — propranolol may increase warfarin plasma levels; monitor INR closely
- Chlorpromazine and other antipsychotics — mutual inhibition of metabolism; additive hypotensive effects
- Cimetidine — reduces hepatic metabolism of propranolol, increasing plasma levels; monitor for enhanced beta-blockade effects
- Rifampicin — significantly increases propranolol metabolism, reducing its plasma levels and antihypertensive efficacy; dose adjustment may be required
CLINICAL NOTE (Kenya-specific): Propranolol holds a unique position in Kenyan clinical practice due to its inclusion on the Kenya Essential Medicines List, its exceptional affordability, and its unmatched breadth of indications. Several Kenya-specific considerations are critically important. The absolute contraindication in asthma is particularly significant in Kenya, where asthma has a high and increasing prevalence — pharmacists dispensing propranolol must screen all patients for asthma and bronchospasm history before dispensing. The masking of hypoglycaemia symptoms is a major concern in Kenya’s growing diabetic population, where sulphonylureas (including glimepiride and glibenclamide) are widely prescribed — concurrent use of propranolol with these agents requires detailed patient education and intensified blood glucose monitoring. Propranolol’s efficacy in migraine prophylaxis is clinically valuable in Kenya, where migraine is significantly under-treated. Its role in managing the adrenergic symptoms of thyrotoxicosis is important given the high prevalence of thyroid disorders in Kenya. For portal hypertension prophylaxis of variceal bleeding — propranolol is the cornerstone of primary and secondary variceal prevention in Kenyan patients with liver cirrhosis, where alcohol-related and viral hepatitis-related liver disease carry substantial burden. Clinicians should note that propranolol’s relatively short half-life of 3–6 hours necessitates twice to four times daily dosing for most cardiovascular indications — a dosing burden that may challenge adherence in Kenya; modified-release propranolol formulations should be considered where available for once-daily dosing.
Keep out of reach of children. Store all medicines safely and securely.
Storage Instructions
- Store below 25°C in a cool, dry place
- Protect from direct sunlight, moisture, and excessive heat
- Keep tablets in their original packaging
- Store out of reach and sight of children
- Do not use after the expiry date printed on the packaging
- Do not transfer tablets to another container
- Dispose of unused or expired tablets safely at your local registered pharmacy — do not flush down the toilet or discard in household waste
Mandatory Disclaimer
This medicine requires a valid prescription. Do not use without medical advice. Propranolol 40 mg is a Prescription Only Medicine (POM) that must be initiated, monitored, and adjusted exclusively by a licensed healthcare provider. Do not self-prescribe, purchase without a valid prescription, or share this medicine with others. Never stop taking propranolol suddenly without medical guidance — abrupt discontinuation is dangerous and can cause life-threatening cardiac events. Propranolol is absolutely contraindicated in asthma — never use this medicine if you have asthma or a history of bronchospasm. Regular medical follow-up including heart rate and blood pressure monitoring is a non-negotiable component of safe propranolol therapy. This product information is provided for general educational reference only and does not constitute medical advice or replace the guidance of a qualified healthcare professional.
Reviews
There are no reviews yet.